ClinicalTrials.gg
CompletedNCT05861778ZIRDOSE-CPUpdated Dec 11, 2023

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

A Phase 1 interventional study of 89Zr-Girentuximab in Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma and Recurrent Renal Cell Cancer, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Telix Pharmaceuticals (Innovations) Pty Limited (part of Telix Pharmaceuticals Limited) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 234 studies in Carcinoma, Renal Cell with a site in China — 111 open to participants now, 141 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Enrollment
177th of 189
10 · median 66
Started
2023
with 29 others
Phase 1
40 of 234
19 open now
Registered
104th of 234
by date

Among the 234 studies in Carcinoma, Renal Cell with a site in China, this one is the 177th largest by enrollment of the 189 interventional ones that give a count, is one of 30 that started in 2023, is one of 40 in phase 1, and was the 104th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

111 of the 234 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
  • Suspected Recurrent Renal Clear Cell Carcinoma
  • Recurrent Renal Cell Cancer

Keywords

  • indeterminate renal masses
  • Suspected Recurrent Renal Clear Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed written
  2. Chinese male or female≥18 years old.
  3. Have an indeterminate renal mass, suspected renal cell carcinoma, or previously diagnosed ccRCC, suspected recurrence on the pre-screening imaging from Day -90 to Day -1
  4. Negative serum pregnancy test for female subjects of at screening. Confirmed negative urine pregnancy test within 24 hours prior to administration of product.
  5. Expected survival ≥ 6 months.
  6. Agree to follow appropriate and highly effective method for at least 35 days after the administration of 89Zr-TLX250.

Exclusion criteria

Exclusion Criteria:

  1. Renal mass is known to be a of another primary tumor.
  2. Have other that require treatment.
  3. Planned antineoplastic therapies (for the period between IV administration of 89Zr-TLX250 and imaging).
  4. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the planned administration of 89Zr-TLX250 or such therapy resulted in a persistent adverse event (> Grade 1) (per National Cancer Institute-Common Toxicity Criteria version 5.0 [NCICTCAE v5.0]).
  5. Exposure to murine or chimeric antibodies within the last 5 years.
  6. Prior use of radionuclides with an interval of less than 10 halflives.
  7. Exposure to any diagnostic or therapeutic agent within the first 4 weeks or 5 half-lives (whichever is longer) of the planned administration of 89Zr-TLX250.
  8. Renal insufficiency with (GFR) ≤ 60 mL/min/1.73 m².
  9. Uncontrolled psychiatric disorders.
  10. Women who are pregnant or breastfeeding.
  11. Known to girentuximab or DFO (deferoxamine).
  12. Have a serious non-malignant disease (e.g., infectious disease, disease, or metabolic disease) that, in the opinion of the investigator, may interfere with the purpose of the study or subject safety or compliance.
  13. Vulnerable population (e.g., being in detention).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    89Zr-girentuximab

    A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab

    Drug: 89Zr-Girentuximab

Interventions

  • A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.

    Also known as: 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx

06

What researchers measure

Primary outcomes

  1. Safety parameter Physical Examination

    Frequency of occurrence and severity of abnormal findings in safety investigations regarding the physical examination.

    Time frame: 9 days

  2. Safety parameter Vital Signs

    Frequency of occurrence and severity of abnormal findings in safety investigations regarding the Vital signs

    Time frame: 9 days

  3. Safety parameter Laboratory examinations

    Frequency of occurrence and severity of abnormal findings in safety investigations regarding Laboratory examinations.

    Time frame: 9 days

  4. Safety parameter concomitant medications

    Frequency of occurrence and severity of abnormal findings in safety investigations regarding concomitant medications.

    Time frame: 9 days

  5. Safety parameter ECG

    Frequency of occurrence and severity of abnormal findings in the 12-lead ECG (ECG QT Interval)

    Time frame: 9 days

Secondary outcomes

  1. Whole blood radioactivity PK parameters

    This outcome will be measured by analysing the radioactivity present in the blood at baseline (pre-dose), 0.5h, 1h, 2h, 4h, 24h, 72h and Day 5+/-1 day. Assessments include: Cmax (maximum concentration)

    Time frame: 6 days

  2. Radiation dosimetry

    whole body PET/CT scans will be acquired in supine position at 0.5, 4, 24, 72 and 168±24 h (Day 7±1) post injection, using low dose CT without contrast agent. Normalized Absorbed Dose = Absorbed Dose/ Administered Dose

    Time frame: 8 days

  3. Tumour dosimetry

    Normalised whole body effective radiation dose (mSv/MBq)

    Time frame: Whole body PET/CT scans will be acquired in supine position at 0.5, 4, 24, 72 and 168±24 h (Day 7±1) post injection

07

Study locations

1 site
  • Peking University Cancer Hospital & Institute
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Nov 2023, 5 months.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 5 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
May 17, 2023
StartActual
Jun 26, 2023
Primary completionActual
Nov 27, 2023
CompletionActual
Nov 27, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05861778
Collaborators
Grand Pharmaceutical (China) Co., Ltd.
Responsible party
Sponsor
First posted
May 17, 2023
Start date
Jun 26, 2023
Primary completion
Nov 27, 2023
Completion
Nov 27, 2023
Last update
Dec 11, 2023

Study contacts

Zhi Yang
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zirconium Zr 89 Girentuximab

Start the discussion